Inflammatory Arthritis Complicating Galactosialidosis: A Case Report

F. Verkuil (f.verkuil@amsterdamumc.nl)
Emma Kinderziekenhuis AMC  https://orcid.org/0000-0002-4544-1235

A.M. Bosch
Emma Kinderziekenhuis AMC Locatie AMC: Emma Kinderziekenhuis Amsterdam UMC

P.A.A. Struijs
Amsterdam UMC - Locatie AMC: Amsterdam UMC Locatie AMC

R. Hemke
Amsterdam UMC - Locatie AMC: Amsterdam UMC Locatie AMC

J.M. van den Berg
Emma Kinderziekenhuis AMC Locatie AMC: Emma Kinderziekenhuis Amsterdam UMC

Case Report

Keywords: Lysosomal storage disorder, Galactosialidosis, Inherited metabolic disorder, Inflammatory arthritis, Joint inflammation, Synovitis, Children

DOI: https://doi.org/10.21203/rs.3.rs-104390/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Galactosialidosis (GS) is a rare inherited lysosomal storage disorder (LSD) which is characterized by a defect in the lysosomal glycoprotein catabolism. We report, for the first time, the case of a child affected by GS presenting with recurrent episodes of extensive joint inflammation in both knee joints. The aim of this case-report is to describe the clinical presentation as well as the laboratory, radiologic and microscopic features of this unique presentation of GS. Furthermore, we explore inflammatory mechanisms potentially responsible for the origination of the arthritic joint pathology observed in our patient.

Case presentation

We describe the rare case of a 12-year-old boy diagnosed with GS (late infantile form) who presented with multiple episodes of inflammatory arthritis involving both knees; no other joints were suspected for joint inflammation. Laboratory results did not indicate an autoimmune disorder. Synovial fluid tested negative for any bacterial infection and ruled out a malignancy and crystal induced arthritis. Microscopic examination of the synovial tissue revealed numerous foamy macrophages with extensive vacuolization, consistent with the previous diagnosis of GS. Treatment consisted of aspiration of excessive joint fluid and subsequent intra-articular injection of triamcinolonehexacetonide with excellent but transient result. Given the evidence of storage products within macrophages of the inflamed synovial tissue and the absence of other etiological clues, GS itself was considered as the primary cause for the relapsing inflammatory joint pathology. According to the restricted data on articular manifestations in GS, to date, GS cannot be linked directly to joint inflammation. Nevertheless, in several other LSDs, the accumulation of storage material has been associated with numerous osteoimmunological changes that might play a role in the pathophysiology of arthritic processes.

Conclusions

We hypothesize that the articular build-up of GS storage products triggered systemic as well as local inflammatory processes, resulting in the extensive inflammatory joint pathology as observed in our patient. Future identification of other patients with GS is required to corroborate the existence of an arthritic clinical phenotype of GS and to assess the underlying pathophysiology.

Background

Galactosialidosis (GS; MIM #256540) is a rare autosomal recessive lysosomal storage disorder (LSD) characterized by malfunction of the lysosomal glycoprotein degradation and subsequent intra-lysosomal accumulation of sialyloligosaccharides and glycopeptides. In GS, the primary biochemical defect is the deficiency of the lysosomal protective protein/cathepsin A (PPCA), encoded by the CTSA gene which is located on chromosome 20q13.1. One of the major functions of PPCA is the formation of a multienzyme
complex with alpha-N-acetyl neuraminidase 1 (NEU1; EC 3.2.1.18) and beta-galactosidase 1 (GLB1; EC 3.2.1.23), which ensures the stability of these enzymes and protects both glycosidases from premature proteolytic post-translational modification (1-3). Most patients with GS share some typical clinical features, such as coarse facial features, vertebral deformities, hepatosplenomegaly, cardiac pathology, hearing loss and macular cherry-red-spots. Based on the age of onset and clinical features patients are categorized in a distinct GS subtype: the early infantile, the late infantile or the juvenile/adult type (1, 4). Besides the typical clinical characteristics, some studies also describe patients with articular abnormalities (5-8). Owing to the small number of case reports and brief descriptions of the patients’ phenotype, substantial data about joint pathology in patients with GS is sparse.

Here we report, for the first time, a case of a patient affected by GS who presented with severe osteoarticular manifestations as well as recurrent episodes of inflammatory arthritis in both knees. The aim of this case-report is to describe the clinical presentation as well as the laboratory, radiologic and microscopic features of this rare GS phenotype. Furthermore, we explore inflammatory mechanisms that might play a role in the pathophysiology of the arthritic joint pathology in our patient.

**Case Presentation**

We report a unique case of a 12-year-old boy, previously diagnosed with GS, who visited the Department of Pediatric Rheumatology with relapsing episodes of progressive swelling in the patellar region in both knees.

The patient was the first child of healthy, consanguineous, parents with a Turkish ethnic background. Pregnancy and delivery were uneventful and no abnormalities were observed in the first months of life (in particular normal psychomotor development). At 17 months of age, during an admission for an upper airway infection, an enlargement of the liver, a vertebral deformity and coarsening of the facial features were noted; hence an inborn error of metabolism was suspected. Urine oligosaccharides demonstrated elevations of urinary sialyloligosaccharides and subsequent fibroblast enzyme studies revealed deficient activities of PPCA, GLB1 and NEU1, thus confirming the diagnosis of GS. Since there were no prenatal and perinatal abnormalities the patient was classified as having the late infantile form of GS. During the following years the patient developed more typical GS related clinical characteristics. An overview of the clinical features of GS in our patient is displayed in Table 1. For radiographic images and medical photographs of the musculoskeletal deformities, see Figure 1.

**Table 1.** Overview of clinical manifestations of GS (late infantile form) in a 12-year-old patient
At the age of 8 years, the boy presented at the Department of Orthopedic Surgery for follow-up in the management of disease-related skeletal and joint pathology (see Table 1), and mild swelling in the right knee was reported for the first time. The initial work-up consisted of whole-leg X-rays, since a disease-related orthopedic cause was suspected. The X-rays showed progression of pre-existing valgus malalignment in both knees and a temporary hemi-epifysiodesis was considered necessary. However, the progressive swelling of the knee was not explained by the angular knee deformities, since the X-rays showed no signs of osteoarthritis (i.e. no joint space narrowing, osteophyte formation or arthrosis). Ultrasound and contrast-enhanced magnetic resonance imaging (MRI) of the knee were performed. Severe effusion in the knee joint and extensive thickening of the enhancing synovial membrane were observed (see Figure 2). Since findings on both imaging modalities were highly suspicious for inflammatory pathology, the boy was referred to the pediatric rheumatologist.

The boy presented to the Pediatric Rheumatology Department with progressive swelling in the patellar region of the right knee since 3 months. He reported mild pain during physical activity in the right knee. No morning stiffness, nocturnal pain, fever, history of trauma, tick bite before the onset of the swelling nor previous episodes of joint swelling were reported. The patient did not describe any pain or swelling of other joints. Pre-existing limited range of motion in multiple joints secondary to the GS related flexion contractures were reported as not progressive. Medical family history was negative for auto-immune disorders. Body height was 111 centimetres (<-3 SD) and body weight was 19 kilograms (+0.5 SD; corrected for height). Physical examination revealed warmth and severe swelling of the right knee. No
other joints were suspected for arthritis. Laboratory investigations revealed no abnormalities (i.e. differential blood count: normal, leukocyte count: 4.7x10^9/L [reference range: 4-14x10^9/L], C-reactive protein: 1.1 mg/L [reference range: 0-5 mg/L], antistreptolysin titer: negative, Borrelia serology: negative, human leukocyte antigen-B27: negative, anti-nuclear antibody test [ANA]: negative, IgM rheumatoid factor: 18.0 kU/L [reference range: 0-49 kU/L] and anti-cyclic citrullinated peptide antibody: 9 kAU/L [reference range: 0-25 kAU/L]). The initial differential diagnosis included juvenile idiopathic arthritis (JIA), infectious arthritis, reactive arthritis and malignancy.

Four months after presentation to the pediatric rheumatology service, diagnostic arthroscopy of the right knee was combined with bilateral hemi-epiphysiodesis (using 8-plates [orthofix®, Lewisville USA]). During the arthroscopy severe synovitis in the joint space of the right knee was observed. Synovial tissue and fluid were obtained and sent to the Department of Pathology and Medical Microbiology for examination. Synovial fluid assessment revealed high cellularity and mononuclear cell infiltration. Cell analysis showed a significant predominance of macrophages. Additionally, synovial fluid tested negative for any bacterial infection (in particular no detection of Mycobacterium tuberculosis or Borrelia spirochetes). Furthermore, the synovial fluid was not suspicious for a malignancy nor crystal induced arthritis. Microscopic examination of the synovial tissue revealed numerous foamy macrophages with extensive vacuolization, consistent with the previous diagnosis of GS. After the exclusion of infectious arthritis and malignancy, the patient was treated with an intra-articular corticosteroid injection (triamcinolonehexacetonide 1 mg/kg). The swelling reduced significantly during follow-up and had almost disappeared entirely after 6 months.

During the next 4 years the patient presented with three more episodes of progressive swelling of the other knee joint. Clinical history, physical examination (except for the location of joint inflammation) and laboratory results were virtually identical to the first episode. Treatment consisted of aspiration of excessive joint fluid and subsequent intra-articular injection of triamcinolonehexacetonide, which was highly effective in all episodes, as displayed in Figure 3. The duration of clinical remission after injection of corticosteroids was approximately 1 year.

Over the years the patient did not develop any signs suggestive of arthritis in other joints, iridocyclitis, inflammatory bowel disease or skin rashes/psoriasis.

**Discussion And Conclusions**

GS is a rare LSD which presents with a wide range of clinical features. The musculoskeletal system is one of the organ systems typically affected, resulting in varying degrees of musculoskeletal deformities (1). A few studies also report patients with articular complaints (5-8), yet knowledge on GS-related joint pathology is limited. Our patient exhibits a remarkable frequency and severity of osteoarticular abnormalities and in addition presented with severe relapsing inflammatory arthritis in both knees, which has never been described before. The differential diagnosis for arthritis in the pediatric population is broad and therefore it can be challenging to obtain a correct diagnosis (9, 10). In the present case, owing
to comprehensive examinations (i.e. physical examination, laboratory tests, radiologic imaging and microscopic examination) multiple possible causes for the recurrent inflammatory joint pathology could be rejected (in particular there were no signs of infectious arthritis, reactive arthritis, osteoarthritis, arthritis secondary to a malignancy or crystal induced arthritis). However, the clinical results were not conclusive and therefore the primary cause for the recurrent arthritis remains elusive.

A diagnosis which could explain the clinical picture is the JIA subtype: ANA negative oligo-articular JIA. JIA is the most common acquired chronic musculoskeletal pediatric disease and defined by joint inflammation, of unknown origin, that persist for more than 6 weeks and starts before the age of 16 years (10). JIA is a diagnosis per exclusionem (10), and therefore should be considered as a possible diagnosis in this case. However, microscopic examination in our patient showed numerous foamy macrophages with extensive vacuolization in the synovial tissue of the inflamed joint, which is not associated with JIA. Given the evidence of storage products within the macrophages of the inflamed synovial tissue and no conclusive diagnosis, GS itself should be considered as the primary cause for the recurrent arthritis. We hypothesize that the prolonged articular build-up of storage material has induced arthritic cascades, resulting in the development of the inflammatory joint pathology as observed in our patient.

According to the sparse literature on joint complaints in GS, to date, GS cannot be linked directly to joint inflammation. Nevertheless, disease-related arthritis has been described in several other LSDs, such as: Fabry disease (MIM #301500) (11), Farber lipogranulomatosis (MIM #228000) (12-16), Gaucher disease (MIM #230800) (16-19), α-Mannosidosis (MIM #248500) (20), Fucosidosis (MIM #230000) (21), Aspartylglucosaminuria (MIM #208400) (22), Cystinosis (MIM #219800) (23) and in a number of subtypes of Mucopolysaccharidoses (MPSs) (24-26). Although, some arthritic mechanisms seem to be LSD specific (e.g. vascular occlusion secondary to bone marrow infiltration with storage cells in Fabry disease (27) and Gaucher disease (28), and crystal induced arthritis in Cystinosis (29)), systemic as well as local inflammatory processes possibly related to the effects of prolonged articular build-up of storage material in general have been reported. For instance, the abundance of unmetabolized substrates in LSDs might induce aberrant immune responses with subsequent expansion of immune cells of the innate immunity as well as adaptive immunity (26, 30-34). Moreover, it is thought that storage products in MPSs possibly could act as self-antigens and subsequently might provoke the necessary signals to activate autoimmunity processes (35). Another potential key player in LSD related joint inflammation could be the increased activation of Toll Like Receptor 4 (TLR4), as described in MPSs (26, 36). TLR4 activation is related to the upregulation of numerous pro-inflammatory proteins, such as chemokines, cytokines (e.g. tumor necrosis factor [TNF] and interleukin-1 [IL1]), nitro oxide products, metalloproteinases, prostanoids and growth factors (26, 36). Since the cause for storage product deposition in LSDs cannot be eliminated, the trigger for the above described inflammatory cascades is continuously present and therefore eventually might lead to persistent inflammatory activity known as metabolic inflammation (26). Activation of TLR4 does not only have systemic effects, but also induces local mechanisms which show several similarities to arthritic processes observed in rheumatoid arthritis. For example, the increased levels of TNF and IL1 could result in hyperproliferation of immature synoviocytes and subsequent synovial hyperplasia (26, 36). Despite all the aforementioned inflammatory processes, extensive joint
inflammation in LSDs, similar to the arthritic joint pathology as observed in our patient, is rare and, to our knowledge, has only been described in 3 children diagnosed with MPS-IX (25). According to the fact that the vast majority of patients suffering from LSDs do not exhibit inflammatory arthritis, presence of genetic susceptibility for development of autoimmune responses to storage material should be considered in our case.

In this study, we report, for the first time, the case of a boy affected by GS presenting with relapsing inflammatory arthritis in both knees. Given the evidence of storage material in the inflamed synovial tissue and absence of clues typical for other potential diagnoses, GS itself is considered as the primary cause for the origination of the inflammatory arthritis. Based on literature about joint inflammation complicating LSDs, we hypothesize that the chronic articular accumulation of GS storage products triggered local as well as systemic arthritic responses, resulting in the recurrent episodes of inflammatory joint pathology in our patient. Nevertheless, future identification of other patients with GS is required to corroborate the existence of an arthritic clinical phenotype of GS and to assess the underlying pathophysiology.

**Abbreviations**

**ANA:** Anti-nuclear antibody; **GLB1:** beta-Galactosidase 1; **GS:** Galactosialidosis; **IL1:** Interleukin-1; **JIA:** Juvenile idiopathic arthritis; **LSD:** Lysosomal storage disease; **NEU1:** alpha-N-acetyl Neuraminidase 1; **MPS:** Mucopolysaccharidosis; **MRI:** Magnetic resonance imaging; **PIP:** Proximal interphalangeal; **PPCA:** Protective Protein/Cathepsin A; **TLR4:** Toll Like Receptor 4; **TNF:** Tumor necrosis factor

**Declarations**

**Ethics approval and consent to participate:** Not applicable.

**Consent for publication:** Written informed consent was provided by the legal guardians (parents) of the patient for the publication of all medical data (including medical photographs).

**Availability of data and material:** Contact authors for data requests.

**Competing interests:** The authors of this manuscript declare that they have no competing interests.

**Funding:** The authors declare that they did not receive any financial support for the research efforts, publication and/or authorship of this manuscript.

**Authors' contributions:** FV participated in background research, data acquisition, data analysis and interpretation, and drafting of the manuscript under the supervision of JB (i.e. coordination, critical review and feedback throughout all study stages). JB, AB, PS and RH participated in data acquisition and revision/modification of the manuscript. All authors read and approved the final manuscript.
Acknowledgements: The authors are grateful to the legal guardians of the patient for providing informed consent to publish all medical data.

References

1. d’Azzo A, Andria G, Bonten E, Annunziata I. Galactosialidosis. In: Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson KM, et al., editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: The McGraw-Hill Companies, Inc.; 2014.

2. d’Azzo A, Bonten E. Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease. Biochemical Society transactions. 2010;38(6):1453-7.

3. d’Azzo A, Hoogeveen A, Reuser AJ, Robinson D, Galjaard H. Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proceedings of the National Academy of Sciences of the United States of America. 1982;79(15):4535-9.

4. Okamura-Oho Y, Zhang S, Callahan JW. The biochemistry and clinical features of galactosialidosis. Biochimica et biophysica acta. 1994;1225(3):244-54.

5. Orii T, Nakao T. A new type of mucolipidosis with beta-galactosidase deficiency and glycopeptiduria. Jinrui idengaku zasshi The Japanese journal of human genetics. 1974;19(1):61-2.

6. Suzuki Y, Nakamura N, Fukuoka K, Shimada Y, Uono M. beta-Galactosidase deficiency in juvenile and adult patients. Report of six Japanese cases and review of literature. Human genetics. 1977;36(2):219-29.

7. Zhou XY, van der Spoel A, Rottier R, Hale G, Willemsen R, Berry GT, et al. Molecular and biochemical analysis of protective protein/cathepsin A mutations: correlation with clinical severity in galactosialidosis. Human molecular genetics. 1996;5(12):1977-87.

8. Chitayat D, Applegarth DA, Lewis J, Dinnick JE, McCormick AQ, Hall JG. Juvenile galactosialidosis in a white male: a new variant. American journal of medical genetics. 1988;31(4):887-901.

9. Giancane G, Consolaro A, Lanni S, Davi S, Schiappapietra B, Ravelli A. Juvenile Idiopathic Arthritis: Diagnosis and Treatment. Rheumatology and therapy. 2016;3(2):187-207.

10. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet (London, England). 2007;369(9563):767-78.

11. Lidove O, Zeller V, Chicheportiche V, Meyssonier V, Sene T, Godot S, et al. Musculoskeletal manifestations of Fabry disease: A retrospective study. Joint, bone, spine : revue du rhumatisme. 2016;83(4):421-6.

12. Kim YJ, Park SJ, Park CK, Kim SH, Lee CW. A case of Farber lipogranulomatosis. Journal of Korean medical science. 1998;13(1):95-8.

13. Kostik MM, Chikova IA, Avramenko VV, Vasyakina LI, Le Trionnaire E, Chasnyk VG, et al. Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis. Journal of inherited metabolic disease. 2013;36(6):1079-80.

14. Teoh HL, Solyom A, Schuchman EH, Mowat D, Roscioli T, Farrar M, et al. Polyarticular Arthritis and Spinal Muscular Atrophy in Acid Ceramidase Deficiency. Pediatrics. 2016;138(4).
15. Moser HW, Prensky AL, Wolfe HJ, Rosman NP. Farber’s lipogranulomatosis. Report of a case and demonstration of an excess of free ceramide and ganglioside. The American journal of medicine. 1969;47(6):869-90.

16. Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nature reviews Disease primers. 2018;4(1):27.

17. Brisa G, Di Rocco M, Picco P, Damasio MB, Martini A. Coxarthrosis as the presenting symptom of Gaucher disease type 1. Arthritis. 2011;2011:361279.

18. Weizman Z, Tennenbaum A, Yatziv S. Interphalangeal joint involvement in Gaucher’s disease, type I, resembling juvenile rheumatoid arthritis. Arthritis and rheumatism. 1982;25(6):706-7.

19. Katz K, Kornreich L, Horev G, Ziv N, Soudry M, Cohen IJ. Involvement of the foot and ankle in patients with Gaucher disease. Foot & ankle international. 1999;20(2):104-7.

20. Weiss SW, Kelly WD. Bilateral destructive synovitis associated with alpha mannosidase deficiency. The American journal of surgical pathology. 1983;7(5):487-94.

21. Wynne E, Wynne K, Cleary M, Brogan PA. Fucosidosis mimicking juvenile idiopathic arthritis. Rheumatology advances in practice. 2018;2(2):rky040.

22. Arvio MA, Rapola JM, Pelkonen PM. Chronic arthritis in patients with aspartylglucosaminuria. The Journal of rheumatology. 1998;25(6):1131-4.

23. Stepan J, Pitrova S, Pazderka V. Cystinosis with crystal-induced synovitis and arthropathy. Zeitschrift fur Rheumatologie. 1976;35(9-10):347-55.

24. Oussoren E, Brands MM, Ruijter GJ, der Ploeg AT, Reuser AJ. Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochim Biophys Acta. 2011;1812(11):1542-56.

25. Imundo L, Leduc CA, Guha S, Brown M, Perino G, Gushulak L, et al. A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis. Journal of inherited metabolic disease. 2011;34(5):1013-22.

26. Opoka-Winiarska V, Jurecka A, Emeryk A, Tylki-Szymanska A. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation. Osteoarthritis and cartilage. 2013;21(12):1813-23.

27. O’Neill F, Rice J. Avascular necrosis of bilateral femoral heads in a patient with Fabry’s disease. Hip international : the journal of clinical and experimental research on hip pathology and therapy. 2012;22(1):119-21.

28. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. The British journal of radiology. 2002;75 Suppl 1:A2-12.

29. Avenarius DFM, Ording Muller LS, Rosendahl K. Joint Fluid, Bone Marrow Edemalike Changes, and Ganglion Cysts in the Pediatric Wrist: Features That May Mimic Pathologic Abnormalities-Follow-Up of a Healthy Cohort. AJR American journal of roentgenology. 2017;208(6):1352-7.
30. Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Molecular genetics and metabolism. 2017;122(3):19-27.

31. Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatric rheumatology online journal. 2007;5:15.

32. Pandey MK, Grabowski GA. Immunological cells and functions in Gaucher disease. Critical reviews in oncogenesis. 2013;18(3):197-220.

33. Pandey MK, Burrow TA, Rani R, Martin LJ, Witte D, Setchell KD, et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017;543(7643):108-12.

34. Pandey MK, Grabowski GA, Kohl J. An unexpected player in Gaucher disease: The multiple roles of complement in disease development. Seminars in immunology. 2018;37:30-42.

35. Wang J, Roehrl M. Glycosaminoglycans are a potential cause of rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:14362-7.

36. Simonaro CM, D'Angelo M, He X, Eliyahu E, Shtraizent N, Haskins ME, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol. 2008;172(1):112-22.